Efficacy, Safety, and Molecular Response Predictors of Oral Ixazomib and Short-Course Rituximab in Untreated Indolent B-Cell Non-Hodgkin Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Blood Advances
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy, Safety, and Molecular Response Predictors of Oral Ixazomib and Short-Course Rituximab in Untreated iNHL
Blood Adv 2022 Nov 16;[EPub Ahead of Print], SA Graf, R Lynch, CS Ujjani, TA Gooley, H Rasmussen, DG Coffey, AJ Cowan, SD Smith, M Shadman, EH Warren, E Libby, AL Greninger, JR Fromm, AK GopalFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.